AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 281 min read$UTHR

ROTHBLATT MARTINE A sold $5.6M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $587.73 ($582.66–$592.84, $5.58M total) across 11 trades on 2026-10-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Oct 28, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Neutral
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRNeutralLow
01

Why it matters

The disclosed sale adds supply to the market and may be interpreted as a neutral to slightly bearish signal for UTHR.

02

Market read

Primary insider sale of $5.6M; modest relevance for short‑term traders monitoring biotech stocks.

03

What to watch

Potential upcoming clinical data or partnership announcements could offset sell‑off pressure.

Relevance 5/10Novelty 5/10Timing: post‑market filing on Oct 28

Background

Form 4 filing discloses insider transactions required by SEC; such filings are primary sources of material insider activity.

Company-level read

Ticker impact

$UTHRNeutralMedium confidence
Context

Chairperson & CEO Martine Rothblatt sold $5.6M of United Therapeutics shares via a 10b5‑1 plan, reducing her stake to 324,443 shares.

Expected impact

likely slight downward pressure as market prices in the insider sell.

Evidence & confidence

The sale is sizable for a mid‑cap biotech and was executed through a pre‑arranged plan, suggesting no urgent distress but still adds supply pressure.

Market effects

Sector

May prompt short‑term caution in biotech sector but unlikely to shift broader trends.

Regional

Limited to U.S. investors; no regional ripple.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The sale could be routine under a 10b5‑1 plan and not indicative of negative fundamentals.

Key entities

  • company
    United Therapeutics Corp

    Biopharmaceutical company developing therapies for pulmonary arterial hypertension and other conditions.

  • person
    Martine A. Rothblatt

    Chairperson & CEO of United Therapeutics, insider reporter of the transaction.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 28
$UTHRMed

United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH Treatment

United Therapeutics (UTHR) received FDA clearance to start clinical trials for Treprostinil-Iloprost SMI, an inhaled treatment for pulmonary arterial hypertension (PAH). The phase 1 trial will assess safety and tolerability. The therapy aims to address symptom flare-ups between maintenance doses. UTHR plans a phase 2 trial in 2027 if initial results are positive. PAH affects around 500,000 people globally.

finance.yahoo.com2 min
OCT 28
$UTHRMed

FDA clears a trial of a two-drug inhaler that could be the first as-needed therapy for lung artery disease.

The FDA approved a trial for Treprostinil-Iloprost SMI, a potential first as-needed inhaler therapy for pulmonary arterial hypertension (PAH). United Therapeutics plans a phase 1 study in 2026, with a phase 2 study in PAH patients anticipated in 2027. The therapy combines treprostinil and iloprost, aiming to provide episodic symptom relief. United Therapeutics aims to expand its PAH treatment portfolio.

stocktitan.net2 min